AOD-9604 is one of the more carefully-designed peptides in the research literature — and also one of the clearest examples of a compound whose preclinical promise did not survive contact with a properly powered human trial.
What: A modified 16-amino-acid fragment of human growth hormone (residues 177-191 plus an added tyrosine), designed to isolate hGH's fat-mobilizing activity from its growth-promoting activity.
Research areas: Lipolysis (fat breakdown) · Obesity drug development · Cartilage and chondrocyte biology · Growth hormone structure-function
Evidence: Supportive preclinical data in rodents, acceptable Phase 1 safety — but the pivotal Phase 2b obesity trial failed to meet its primary weight-loss endpoint.
Status: Not approved as a medicine anywhere. GRAS food-ingredient status in the US is a food-safety classification, not a therapeutic endorsement. WADA-prohibited.
What is AOD-9604?
AOD-9604 — "Anti-Obesity Drug 9604" — is a synthetic 15-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone, specifically residues 177 to 191 of the hGH sequence, with a tyrosine residue added at the N-terminus to improve stability. The sequence is:
The rationale behind the molecule is elegant. Full-length human growth hormone has multiple biological activities, including effects on growth, IGF-1 production (IGF-1 is a hormone that mediates most of hGH's growth effects), and — separately — a lipolytic (fat-mobilizing) activity that appears to be located in the C-terminal region (the "tail end") of the protein. AOD-9604 was designed to retain the lipolytic region while removing the growth-promoting and IGF-1-stimulating regions, in the hope of producing a selective fat-loss compound without the metabolic side-effects of whole hGH (Ng et al., 2000).
Origin and development
AOD-9604 emerged from the laboratory of Frank Ng and colleagues at Monash University in Australia in the 1990s, building on earlier work on the lipolytic properties of the hGH C-terminal region. The compound was subsequently licensed to Metabolic Pharmaceuticals Ltd, an Australian biotechnology company that advanced it into human clinical trials as an investigational obesity therapeutic (Heffernan et al., 2001).
Through the early 2000s, AOD-9604 moved through a typical early-stage clinical development pathway: Phase 1 safety studies, then Phase 2 efficacy studies. For a time, the program was one of the more visible obesity peptide candidates in the Australian biotech sector. As we will see, the later-stage results did not match the expectations set by the preclinical data.
Proposed mechanisms of action
Lipolysis without hGH-like growth effects
The central mechanistic claim is that AOD-9604 activates lipolytic pathways in adipose tissue without triggering the insulin-antagonizing or growth-promoting activities of whole hGH. Published work from Ng and colleagues reported that the fragment stimulated fat breakdown in isolated rat adipocytes and in whole-animal models while failing to produce the expected rise in IGF-1 that accompanies full hGH administration (Ng et al., 2000).
β3-adrenergic receptor involvement
Some mechanistic studies have proposed that the lipolytic action of AOD-9604 depends, at least in part, on signaling through the β3-adrenergic receptor pathway in adipocytes (fat cells) — the same receptor system targeted by several investigational fat-loss compounds in the 1990s (Stier et al., 2013). The authors proposed that this might explain the selective effect on fat tissue.
Mitochondrial fat oxidation
Other publications have described effects on fat oxidation in mitochondrial preparations, linking the molecule's activity to increased breakdown of stored triglycerides rather than mere redistribution (Heffernan et al., 2000).
No IGF-1 pathway stimulation
A consistent finding across the early literature is that AOD-9604 does not appear to stimulate the IGF-1 axis in the way full-length hGH does. This was the original design goal, and preclinical studies supported it. In principle, this is what makes the molecule interesting: the possibility of a growth-hormone-derived lipolytic effect without the insulin-resistance and growth-promotion issues that complicate full hGH administration (Ng et al., 2000).
The mechanistic story for AOD-9604 is internally coherent and supported by published in-vitro and rodent data. The question — as with many investigational peptides — is whether the mechanism translates into measurable clinical outcomes in humans. For AOD-9604, the answer from the Phase 2b data is less favorable than the mechanism alone would suggest.
Key research areas
Preclinical lipolysis studies
The preclinical literature is where AOD-9604 looks strongest. Published studies reported stimulation of lipolysis in rat adipocyte preparations, reduced body fat accumulation in obese mouse models fed high-fat diets, and preserved lean mass — a favorable combination on paper (Ng et al., 2000). The effect sizes in these studies were large enough to justify clinical development.
Phase 1 human safety trials
Heffernan and colleagues published Phase 1 data describing the pharmacokinetics and short-term safety profile of AOD-9604 in healthy volunteers. The compound was reported to be generally well-tolerated at the doses examined, with a pharmacokinetic profile consistent with a short-half-life peptide (Heffernan et al., 2001).
Phase 2 obesity trials
Metabolic Pharmaceuticals advanced the compound into Phase 2 efficacy studies in obese human subjects. Early reports suggested modest weight-loss signals in the treated groups, which — combined with the favorable safety profile — generated optimism around the program.
The Phase 2b result
It is important to be clear about what happened next, because the later Phase 2b result is frequently glossed over in non-technical coverage.
In the later, larger Phase 2b trial conducted by Metabolic Pharmaceuticals, AOD-9604 failed to meet its primary weight-loss endpoint in obese subjects. The trial did not demonstrate clinically or statistically meaningful weight loss versus placebo at the doses and duration tested. This was a significant negative result for the program, and the commercial development of AOD-9604 as a weight-loss medicine effectively ended at this point (Metabolic Pharmaceuticals, 2007).
The researcher should hold this in mind when reading breathless online descriptions of AOD-9604 as "proven" for fat loss. The peer-reviewed and regulatory trial record does not support that description. A properly powered human efficacy trial was conducted and did not produce the hoped-for outcome.
Cartilage research: a second life
After the obesity program wound down, AOD-9604 reappeared in a separate research context: cartilage and joint biology. Kwon and colleagues published work examining effects of AOD-9604 in cartilage models, reporting pro-anabolic effects on chondrocyte behavior in laboratory settings (Kwon et al., 2015). This line of research is smaller and has not matured into an approved clinical indication.
GRAS status as a food ingredient
In 2011, AOD-9604 received "Generally Recognized as Safe" (GRAS) status from the U.S. FDA as a food ingredient — a regulatory category entirely separate from drug approval. GRAS classification is a safety determination for use in food, not a demonstration of therapeutic efficacy (FDA, 2011). It is frequently quoted in marketing material as though it were an endorsement. It is not.
Current state of evidence
- Strong preclinical data. The in-vitro and rodent literature on AOD-9604 is genuinely supportive of lipolytic activity and favorable mechanism.
- Phase 1 data: acceptable. Human safety and pharmacokinetics were characterized in small healthy-volunteer studies.
- Phase 2b data: negative. The primary weight-loss endpoint was not met in the larger obesity trial.
- GRAS status for food use is unrelated to therapeutic efficacy.
- No regulatory approval as a medicine by the EMA, MHRA, FDA, or any comparable regulator.
- Cartilage research is an active but small secondary line of work.
Regulatory status and WADA
AOD-9604 is not approved as a medicine in any major jurisdiction. It is not a registered pharmaceutical in the European Union, the United Kingdom, or the United States.
The World Anti-Doping Agency prohibits AOD-9604 under its classification for growth hormone fragments and related peptide hormones. The prohibition applies at all times to athletes subject to WADA code. This regulatory status has no bearing on the scientific question of efficacy — it reflects the substance's classification within the anti-doping framework regardless of whether it works (WADA, 2024).
What the research does not show
- No proven weight loss in adequately powered human trials. The Phase 2b trial was the pivotal test, and it did not support the preclinical hypothesis.
- No long-term human safety data. The human exposure that has been characterized is in short-duration trials.
- No head-to-head efficacy comparison with GLP-1 receptor agonists (the current standard for pharmacological weight loss), or with any approved obesity medicine.
- No validated human dosing protocol for any indication in the peer-reviewed trial literature.
- No demonstration of cartilage benefit in humans. The cartilage work remains preclinical.
An honest assessment
A researcher reading the AOD-9604 literature is looking at a compound with three distinct narratives running through it:
The mechanistic story — supported by published preclinical work and internally coherent — suggests a selective lipolytic effect via the hGH C-terminal region without the growth-promoting activity of full hGH. This is scientifically interesting.
The clinical trial story — supported by the Phase 2b outcome — is much less encouraging. The compound did not translate its mechanism into meaningful weight loss in obese humans at the doses and duration tested. Negative trials are normal in drug development, and they matter.
The marketing story — which circulates widely online — tends to cite the preclinical data and skip the negative Phase 2b. This is not an accurate representation of the evidence and the researcher should notice when it happens.
Compared to the GLP-1 class of approved obesity medicines (semaglutide, liraglutide, tirzepatide — the active ingredients in Ozempic, Wegovy, Mounjaro, Zepbound), AOD-9604 has produced far weaker clinical efficacy signals and has never achieved regulatory approval for weight loss in any jurisdiction. This comparison is rarely made in non-technical coverage, but it is the honest framing.
This article is a summary of the published research on AOD-9604. It is not instruction for human use, not medical advice, and not a recommendation for any application. The compound is not an approved medicine. The most important clinical trial in its development program did not support its original indication.